Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Free Cash Flow: 2020-2025

Historic Free Cash Flow for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$13.1 million.

  • SAB Biotherapeutics' Free Cash Flow fell 104.15% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.6 million, marking a year-over-year increase of 2.52%. This contributed to the annual value of -$34.6 million for FY2024, which is 36.79% down from last year.
  • SAB Biotherapeutics' Free Cash Flow amounted to -$13.1 million in Q3 2025, which was down 82.48% from -$7.2 million recorded in Q2 2025.
  • SAB Biotherapeutics' Free Cash Flow's 5-year high stood at $7.6 million during Q1 2021, with a 5-year trough of -$13.5 million in Q4 2023.
  • In the last 3 years, SAB Biotherapeutics' Free Cash Flow had a median value of -$7.8 million in 2024 and averaged -$8.0 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Free Cash Flow plummeted by 72,069.97% in 2021 and then soared by 85.07% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Free Cash Flow (Quarterly) stood at -$7.2 million in 2021, then soared by 76.90% to -$1.7 million in 2022, then plummeted by 707.91% to -$13.5 million in 2023, then climbed by 29.06% to -$9.6 million in 2024, then tumbled by 104.15% to -$13.1 million in 2025.
  • Its Free Cash Flow stands at -$13.1 million for Q3 2025, versus -$7.2 million for Q2 2025 and -$7.8 million for Q1 2025.